Employer Coverage of Weight-Loss Drugs Shifts, Focusing on Diabetes Patients

A growing number of employers in the United States are reassessing their health insurance coverage for weight-loss medications, increasingly limiting benefits to employees diagnosed with diabetes. This shift reflects rising healthcare costs associated with these drugs, alongside questions about equitable access and appropriate utilize.

The Changing Landscape of Employer Coverage

PwC has recently informed its U.S. Staff that the company will no longer cover the cost of weight-loss drugs for employees unless they have a diagnosis of diabetes. This decision follows similar moves by other large employers, signaling a broader trend in the corporate benefits landscape.

GLP-1 Drugs: A Revolution in Weight Management

The surge in demand for glucagon-like peptide-1 (GLP-1) receptor agonist drugs, initially approved for treating type 2 diabetes, has driven up healthcare expenditures. These medications, including semaglutide and tirzepatide, have demonstrated significant efficacy in promoting weight loss, leading to increased off-label prescriptions for individuals without diabetes.

Cost Considerations and Equitable Access

The high cost of GLP-1 drugs is a primary driver behind the changes in employer coverage. Whereas the medications can be highly effective, their price tag—often exceeding $1,000 per month—poses a substantial financial burden for both employers and employees. By restricting coverage to those with diabetes, employers aim to align benefits with medically necessary treatments and manage escalating healthcare costs.

New Formulations and Increased Accessibility

Recent FDA approvals of GLP-1 drugs in pill form, such as Foundayo (orforglipron) from Eli Lilly and Wegovy from Novo Nordisk, offer alternative administration routes and potentially lower costs compared to injectable formulations. Lilly began shipping Foundayo to customers on April 6, 2026, and Amazon announced it would stock the pill at U.S. Kiosks, offering same-day shipping. LillyDirect is also selling Foundayo directly to cash-paying customers for $149 per month for the lowest dose.

Implications for Employees and Healthcare Systems

The shift in employer coverage raises concerns about equitable access to weight-loss treatments. Individuals without diabetes who could benefit from GLP-1 drugs may face financial barriers to obtaining these medications. This could exacerbate health disparities and limit access to effective weight management options for a broader population. The evolving landscape also highlights the need for ongoing discussions about the appropriate use of GLP-1 drugs and the role of employers in supporting employee health and well-being.

Key Takeaways

• Employers are increasingly limiting coverage of weight-loss drugs to employees with diabetes.
• Rising costs of GLP-1 medications are a primary driver of these changes.
• New pill formulations offer potential cost savings and increased accessibility.
• Concerns remain about equitable access to weight-loss treatments for all individuals.